Cargando…

T25. ALTERATIONS OF PLASMA PHOSPHOLIPID FATTY ACID PROFILES ARE ASSOCIATED WITH LOCAL BRAIN STRUCTURAL ABNORMALITIES IN NEUROLEPTIC NAïVE FIRST-EPISODE PSYCHOSIS PATIENTS

BACKGROUND: Alterations in brain structure are among the most robust biological findings in schizophrenia. Also changes in fatty acid profiles including reduced levels of polyunsaturated fatty acids (PUFA) are well replicated in schizophrenia. Being essential for neurodevelopmental processes and str...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langbein, Kerstin, Fleischer, Christian, Kuhnt, Katrin, Gaser, Christian, Smesny, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887432/ http://dx.doi.org/10.1093/schbul/sby016.301

Ejemplares similares

F24. OMEGA-6 PUFA METABOLISM DISTURBED IN PHOSPHO- AND SPHINGOLIPIDS IN NEUROLEPTIC-NAïVE FIRST-EPISODE SCHIZOPHRENIA PATIENTS – A FATTY ACID PROFILING STUDY IN FIVE LIPID FRACTIONS
por: Langbein, Kerstin, et al.
Publicado: (2018)

T23. DYNAMICS OF NEURONAL METABOLISM AFTER THE ACUTE ONSET OF PSYCHOSIS – A TWO YEARS FOLLOW-UP 1H/31P-MR-SPECTROSCOPY STUDY IN NEUROLEPTIC NAïVE UHR TRANSITION PATIENTS
por: Smesny, Stefan, et al.
Publicado: (2018)

T165. ULTRA-HIGH FIELD MORPHOMETRY IN DRUG-NAïVE FIRST EPISODE PSYCHOSIS
por: Das, Tushar, et al.
Publicado: (2018)

T164. STRUCTURAL COVARIANCE IN DRUG-NAïVE FIRST EPISODE PSYCHOSIS: AN ULTRA-HIGH FIELD MRI STUDY
por: Das, Tushar, et al.
Publicado: (2018)

T14. HYPOTHALAMIC-PITUITARY-GONADAL AXIS HORMONES IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE OF PSYCHOSIS AND HEALTHY CONTROLS
por: Teresa Pons-Cabrera, Maria, et al.
Publicado: (2020)

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

T154. WHITE MATTER INTEGRITY, DURATION OF UNTREATED PSYCHOSIS, AND ANTIPSYCHOTIC TREATMENT RESPONSE IN MEDICATION-NAïVE FIRST EPISODE PSYCHOSIS PATIENTS
por: Kraguljac, Nina, et al.
Publicado: (2020)

O6.3. PATTERNS OF GRAY MATTER ABNORMALITIES IN PATIENTS WITH FIRST-EPISODE AND TREATMENT-NAïVE SCHIZOPHRENIA
por: Li, Mingli, et al.
Publicado: (2018)

S150. DOPAMINE SYNTHESIS CAPACITY IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOTIC PATIENTS
por: Sigvard, Anne, et al.
Publicado: (2018)

S6. SLEEP ENDOPHENOTYPES OF SCHIZOPHRENIA: A HIGH-DENSITY EEG STUDY IN DRUG-NAïVE, FIRST EPISODE PSYCHOSIS PATIENTS
por: Castelnovo, Anna, et al.
Publicado: (2020)

S158. REWARD ALTERATIONS IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE-PSYCHOSIS PATIENTS BEFORE AND AFTER TREATMENT WITH A PARTIAL DOPAMINE AGONIST
por: Tangmose, Karen, et al.
Publicado: (2018)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

S57. TREATMENT SATISFACTION IN ACUTE PHASE PSYCHOSIS: COMPARISON BETWEEN ANTIPSYCHOTIC NAïVE AND PREVIOUSLY MEDICATED PATIENTS
por: Stabell, Lena, et al.
Publicado: (2018)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

D1-Dopamine Receptor Availability in First-Episode Neuroleptic Naive Psychosis Patients
por: Stenkrona, Per, et al.
Publicado: (2019)

F181. CHANGE IN PREFRONTAL-LIMBIC MORPHOLOGY AND COGNITION IN DRUG-NAïVE FIRST-EPISODE PSYCHOSIS PATIENTS FOLLOWING ATYPICAL ANTIPSYCHOTIC TREATMENT: A BRIEF LONGITUDINAL STUDY
por: Woodward, Melissa, et al.
Publicado: (2018)

F163. STRUCTURAL AND FUNCTIONAL ALTERATIONS IN THE BRAIN DURING WORKING MEMORY IN MEDICATION-NAïVE PATIENTS AT CLINICAL HIGH-RISK FOR PSYCHOSIS
por: Brønnick, Kolbjørn, et al.
Publicado: (2018)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

O3.8. DORSOLATERAL PREFRONTAL CORTEX IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA: DYNAMIC PHASE COHERENCE OF INFRASLOW OSCILLATIONS
por: Das, Tushar, et al.
Publicado: (2018)

S209. DRUG-NAïVE FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDERS: PHARMACOLOGICAL TREATMENT PRACTICES IN INPATIENT UNITS IN HUNAN PROVINCE, CHINA
por: Zhu, Mengran, et al.
Publicado: (2020)

T231. QUALITY OF LIFE IN ANTIPSYCHOTIC-NAïVE YOUTH: EXPLORING THE INTERPLAY WITH METABOLIC SIDE-EFFECTS
por: Chintoh, Araba, et al.
Publicado: (2020)

F206. A TRANSLATIONAL STUDY OF BEHAVIOR, BRAIN STRUCTURE AND GENE PATHWAY IN ERBB4 KNOCKOUT MICE AND FIRST-EPISODE TREATMENT-NAïVE PATIENTS WITH SCHIZOPHRENIA
por: Zhang, Chengcheng, et al.
Publicado: (2018)

M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT
por: Bojesen, Kirsten, et al.
Publicado: (2020)

Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naïve Patients with Schizophrenia
por: Yao, Jeffrey K., et al.
Publicado: (2010)

F16. GLUTAMATE AND GABA LEVELS IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS ARE ASSOCIATED WITH TREATMENT OUTCOME AFTER 1.5 AND 6 MONTHS
por: Bojesen, Kirsten, et al.
Publicado: (2018)

Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis
por: Ermakova, Anna O., et al.
Publicado: (2018)

O2.2. EVALUATION OF THE RELATIONSHIP BETWEEN GLUTAMATE AND BRAIN CONNECTIVITY IN ANTIPSYCHOTIC-NAïVE FIRST EPISODE PATIENTS – A COMBINED MAGNETIC RESONANCE SPECTROSCOPY AND RESTING STATE FUNCTIONAL CONNECTIVITY MRI STUDY
por: Maximo, Jose, et al.
Publicado: (2020)

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

F9. ALTERATIONS OF NEURONAL METABOLISM IN PATIENT SUBGROUPS AT ULTRA-HIGH RISK FOR PSYCHOSIS ACCORDING TO PACE CRITERIA – A 1H/31P-MR-SPECTROSCOPY STUDY
por: Smesny, Stefan, et al.
Publicado: (2018)

Neuroleptic malignant syndrome in cycloserine-induced psychosis
por: Sawant, Neena S., et al.
Publicado: (2015)

Hair cortisol in drug-naïve first-episode individuals with psychosis
por: Andrade, Elvis H., et al.
Publicado: (2016)

Abnormal Brain Bioenergetics in First-Episode Psychosis
por: Yuksel, Cagri, et al.
Publicado: (2021)

Relationships between dorsolateral prefrontal cortex metabolic change and cognitive impairment in first-episode neuroleptic-naive schizophrenia patients
por: Huang, Man-Li, et al.
Publicado: (2017)

F176. CLINICAL CORRELATES OF CORTICAL STRUCTURE IN ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BEFORE AND AFTER SIX-WEEK TREATMENT WITH A DOPAMINE D2/3 RECEPTOR ANTAGONIST
por: Jessen, Kasper, et al.
Publicado: (2018)

S12. A MACHINE LEARNING FRAMEWORK FOR ROBUST AND RELIABLE PREDICTION OF SHORT- AND LONG-TERM CLINICAL RESPONSE IN INITIALLY ANTIPSYCHOTIC-NAïVE SCHIZOPHRENIA PATIENTS BASED ON MULTIMODAL NEUROPSYCHIATRIC DATA
por: Ambrosen, Karen S, et al.
Publicado: (2020)

Neuroleptic-induced deficit syndrome in bipolar disorder with psychosis
por: Ueda, Satoshi, et al.
Publicado: (2016)

Altered functional connectivity links in neuroleptic-naïve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition
por: Pu, Weidan, et al.
Publicado: (2014)

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015)

Multidimensional predictors of negative symptoms in antipsychotic-naive first-episode psychosis
por: Toll, Alba, et al.
Publicado: (2022)

Movement disorders in neuroleptic-naïve patients with schizophrenia spectrum disorders
por: Ayehu, Moges, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ggjg3b0r4bcjkjambu3udkq0fj